In the ID8 Trp53−/− mouse model of ovarian cancer, we found that combination Aza/NextA treatment recruits immune cells, specifically CD8 and NKT cells that can kill tumor cells (Figs. 5–8). Here, CD8A is linked to ovarian cancer.